BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1555 related articles for article (PubMed ID: 17678953)

  • 1. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
    Lipton SA; Gu Z; Nakamura T
    Int Rev Neurobiol; 2007; 82():1-27. PubMed ID: 17678953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
    Lipton SA
    Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
    Lipton SA
    Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
    Lipton SA
    NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging roles of S-nitrosylation in protein misfolding and neurodegenerative diseases.
    Nakamura T; Lipton SA
    Antioxid Redox Signal; 2008 Jan; 10(1):87-101. PubMed ID: 17961071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S-Nitrosylation and uncompetitive/fast off-rate (UFO) drug therapy in neurodegenerative disorders of protein misfolding.
    Nakamura T; Lipton SA
    Cell Death Differ; 2007 Jul; 14(7):1305-14. PubMed ID: 17431424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redox reactions induced by nitrosative stress mediate protein misfolding and mitochondrial dysfunction in neurodegenerative diseases.
    Gu Z; Nakamura T; Lipton SA
    Mol Neurobiol; 2010 Jun; 41(2-3):55-72. PubMed ID: 20333559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell death: protein misfolding and neurodegenerative diseases.
    Nakamura T; Lipton SA
    Apoptosis; 2009 Apr; 14(4):455-68. PubMed ID: 19130231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases.
    Nakamura T; Lipton SA
    Cell Death Differ; 2011 Sep; 18(9):1478-86. PubMed ID: 21597461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration.
    Uehara T; Nakamura T; Yao D; Shi ZQ; Gu Z; Ma Y; Masliah E; Nomura Y; Lipton SA
    Nature; 2006 May; 441(7092):513-7. PubMed ID: 16724068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S-nitrosylation of critical protein thiols mediates protein misfolding and mitochondrial dysfunction in neurodegenerative diseases.
    Nakamura T; Lipton SA
    Antioxid Redox Signal; 2011 Apr; 14(8):1479-92. PubMed ID: 20812868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing Ca2+-mediated nitrosative stress in neurodegenerative diseases: possible pharmacological strategies.
    Nakamura T; Lipton SA
    Cell Calcium; 2010 Feb; 47(2):190-7. PubMed ID: 20060165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma.
    Seki M; Lipton SA
    Prog Brain Res; 2008; 173():495-510. PubMed ID: 18929130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant protein S-nitrosylation contributes to the pathophysiology of neurodegenerative diseases.
    Nakamura T; Prikhodko OA; Pirie E; Nagar S; Akhtar MW; Oh CK; McKercher SR; Ambasudhan R; Okamoto S; Lipton SA
    Neurobiol Dis; 2015 Dec; 84():99-108. PubMed ID: 25796565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.
    Lipton SA
    Nat Rev Drug Discov; 2006 Feb; 5(2):160-70. PubMed ID: 16424917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.
    Olivares D; Deshpande VK; Shi Y; Lahiri DK; Greig NH; Rogers JT; Huang X
    Curr Alzheimer Res; 2012 Jul; 9(6):746-58. PubMed ID: 21875407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
    Rogawski MA; Wenk GL
    CNS Drug Rev; 2003; 9(3):275-308. PubMed ID: 14530799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.